Abzena Promotes Troy Wright to Senior Vice President and Global Head of Quality
Cambridge, UK and San Diego, CA, 15 December 2021 – Abzena, the leading Partner Research Organization (PRO) for outsourced solutions integrating gene to commercial for large molecules and bioconjugates, announced it has promoted Troy Wright to Senior Vice President and Global Head of Quality. Reporting to Jonathan Goldman MD, CEO, Mr. Wright will be accountable for Abzena’s quality assurance and compliance systems, audits and inspections, and day to day quality control operations across all locations in the UK and USA.
Mr. Wright joined Abzena in August 2021 as Quality Site Head, Sanford, North Carolina. He has extensive experience building high performing teams and quality systems within the biopharmaceutical industry. He is a strong quality professional skilled in External Manufacturing Quality and Operational Excellence. Prior to Abzena, Mr. Wright worked for Amgen Inc. for 21 years in positions of increasing responsibility. His roles included Quality Site Head for Contract Manufacturing Organization, Operations Functional Transformation, Chief of Staff for Worldwide Quality, and most recently Quality Operations Team Lead at the bulk drug substance plant in Rhode Island.
Dr. Goldman commented, “We are pleased to announce Troy’s promotion. In the short time since he joined Abzena, he has brought numerous enhancements to quality and compliance operations at Abzena. Abzena delivers fully integrated gene to GMP manufacturing in biologics, complex large molecules and bioconjugation, under one roof. I am excited to welcome Troy to this important leadership role as we seek to bring novel medicines to patients together with our partners.”
Mr. Wright remarked, “I am truly humbled, proud, and filled with gratitude to have the opportunity to guide the Abzena Quality Team into the future. I’m fortunate to lead an extremely passionate and hardworking team with leaders who believe in the importance of developing staff, delivering to clients, and ultimately improving the lives of patients. I’m looking forward to continuing to evolve the Abzena Quality organization while working with all staff and peers to ensure we have a fit for purpose organization that aligns with the growth of the business.”
For more information, please contact:
Abzena provides the most complete set of solutions in integrated early discovery to mid-phase biotherapeutic and bioconjugation drug development and manufacturing in the biopharmaceutical industry. The company maintains resources around the world, with facilities in the US and UK. Abzena is owned by Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors. For more information, please see www.abzena.com.